MARKET

HTBX

HTBX

Heat Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.12
-0.15
-2.39%
After Hours: 6.11 -0.01 -0.16% 19:15 09/24 EDT
OPEN
6.20
PREV CLOSE
6.27
HIGH
6.29
LOW
6.10
VOLUME
164.72K
TURNOVER
--
52 WEEK HIGH
17.00
52 WEEK LOW
5.22
MARKET CAP
155.43M
P/E (TTM)
-4.7501
1D
5D
1M
3M
1Y
5Y
Heat Biologics Files For U.S. Patent Titled 'IMMUNE-MEDIATED CORONAVIRUS TREATMENTS'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&f=G&l=50&d=PG01&p=1&S1=20210283242&OS=20210283242&RS=20210283242
Benzinga · 09/16 16:50
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at t...
GlobeNewswire · 09/15 11:30
HTBX: September Business Update
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT
Benzinga · 09/12 14:30
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at t...
GlobeNewswire · 09/09 12:30
Heat Biologics to Provide Corporate Update
Conference call scheduled for September 2nd at 11:00 AM ETDURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate th...
GlobeNewswire · 08/30 11:30
Heat Biologics Is Starting To Run Away From Support Toward Resistance
Heat Biologics Inc. (NASDAQ: HTBX) shares traded higher Thursday morning after the company announced the launch of its wholly-owned subsidiary Skunkworx Bio Inc. focused on developing a drug discovery paradigm to enable rapid drug deployment.
Benzinga · 08/26 17:53
Heat Biologics Announces Launch Of Its Skunkworx Bio Subsidiary
Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch
Benzinga · 08/26 12:08
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch of its wholly-owned subsidiary, Skunkworx Bio, Inc. ("Skunkwor...
GlobeNewswire · 08/26 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HTBX. Analyze the recent business situations of Heat Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HTBX stock price target is 20.67 with a high estimate of 33.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 2.66M
% Owned: 10.46%
Shares Outstanding: 25.40M
TypeInstitutionsShares
Increased
12
369.81K
New
6
55.61K
Decreased
9
124.21K
Sold Out
11
289.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jeffrey Wolf
Chief Financial Officer/Controller/Secretary
William Ostrander
Lead Director/Independent Director
John Prendergast
Independent Director
John Monahan
Independent Director
Edward Smith
No Data
About HTBX
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Webull offers kinds of Heat Biologics Inc stock information, including NASDAQ:HTBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTBX stock methods without spending real money on the virtual paper trading platform.